Nls pharmaceutics secures key patent in japan for mazindol er in the treatment of heroin dependence

Zurich, switzerland / accesswire / october 21, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is pleased to announce that its japanese patent application no.

NLSP Ratings Summary

NLSP Quant Ranking